Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma

This trial studies tebentafusp, an immunotherapy drug, as a first-line treatment for metastatic uveal melanoma — a rare eye cancer that has spread to other parts of the body. This drug is designed to work specifically in patients with a particular immune system gene type. **You may be eligible if...** - You have metastatic uveal melanoma that has not been previously treated - You test positive for the HLA-A*0201 gene type (a specific immune marker) - You have measurable tumor on imaging - You are in good enough health to receive treatment **You may NOT be eligible if...** - You have received prior systemic therapy for metastatic uveal melanoma - You do not have the HLA-A*0201 gene type - You have active autoimmune disease - You have serious heart, liver, or other organ problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.